{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:03:58Z","timestamp":1791259438708,"version":"4.1.0"},"reference-count":125,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.rdc.2025.07.007","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T07:42:54Z","timestamp":1758699774000},"page":"623-641","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Management of Lung Manifestations in Idiopathic Inflammatory Myopathies"],"prefix":"10.1016","volume":"51","author":[{"given":"Amita","family":"Krishnan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddharth","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Lammi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.rdc.2025.07.007_bib1","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.semarthrit.2020.11.009","article-title":"Prevalence of interstitial lung disease in polymyositis and dermatomyositis: a meta-analysis from 2000 to 2020","volume":"51","author":"Sun","year":"2021","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.007_bib2","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s40674-018-0110-6","article-title":"Myositis-Related interstitial lung diseases: diagnostic features, treatment, and complications","volume":"5","author":"Shappley","year":"2019","journal-title":"Curr Treatm Opt Rheumatol"},{"issue":"12","key":"10.1016\/j.rdc.2025.07.007_bib3","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"European League against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.rdc.2025.07.007_bib4","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.chest.2023.01.031","article-title":"Diagnosis and management of myositis-associated lung disease","volume":"163","author":"Hallowell","year":"2023","journal-title":"Chest"},{"issue":"9","key":"10.1016\/j.rdc.2025.07.007_bib5","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1474-4422(18)30254-0","article-title":"Classification and management of adult inflammatory myopathies","volume":"17","author":"Selva-O\u2019Callaghan","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.rdc.2025.07.007_bib6","article-title":"Idiopathic inflammatory myopathies related lung disease in adults","author":"Sehgal","year":"2024","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.rdc.2025.07.007_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003121","article-title":"Interstitial lung disease with and without progressive fibrosing phenotype in patients with idiopathic inflammatory myopathies: data from a large multicentric cohort","volume":"9","author":"Zanatta","year":"2023","journal-title":"RMD Open"},{"issue":"5","key":"10.1016\/j.rdc.2025.07.007_bib8","article-title":"Factors associated with interstitial lung disease in patients with polymyositis and dermatomyositis: a systematic review and meta-analysis","volume":"11","author":"Zhang","year":"2016","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.rdc.2025.07.007_bib9","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1097\/RHU.0000000000001350","article-title":"Myositis-Specific antibodies and Myositis-Associated antibodies in patients with idiopathic inflammatory myopathies from the PANLAR Myositis Study Group","volume":"27","author":"Gonz\u00e1lez-Bello","year":"2021","journal-title":"J Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.rdc.2025.07.007_bib10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/25785826.2018.1531188","article-title":"Clinical significance of myositis-specific autoantibodies","volume":"41","author":"Nakashima","year":"2018","journal-title":"Immunol Med"},{"issue":"14","key":"10.1016\/j.rdc.2025.07.007_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/jcm13144055","article-title":"A review of Myositis-Associated interstitial lung disease","volume":"13","author":"Kannappan","year":"2024","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.007_bib12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10067-015-3139-z","article-title":"Predictive factors of rapidly progressive-interstitial lung disease in patients with clinically amyopathic dermatomyositis","volume":"35","author":"Xu","year":"2016","journal-title":"Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.rdc.2025.07.007_bib13","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/art.41105","volume":"72","author":"Tsuji","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.rdc.2025.07.007_bib14","article-title":"Rapidly progressive interstitial lung disease risk prediction in anti-MDA5 positive dermatomyositis: the CROSS model","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"issue":"12","key":"10.1016\/j.rdc.2025.07.007_bib15","article-title":"Clinical and radiological features of interstitial lung diseases associated with polymyositis and dermatomyositis","volume":"58","author":"Palmucci","year":"2022","journal-title":"Medicina (Kaunas)"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.007_bib16","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.autrev.2018.07.013","article-title":"Treatment of idiopathic inflammatory myositis associated interstitial lung disease: a systematic review and meta-analysis","volume":"18","author":"Barba","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"8","key":"10.1016\/j.rdc.2025.07.007_bib17","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/j.rmed.2007.02.017","article-title":"Two distinct clinical types of interstitial lung disease associated with polymyositis-dermatomyositis","volume":"101","author":"Won Huh","year":"2007","journal-title":"Respir Med"},{"issue":"6","key":"10.1016\/j.rdc.2025.07.007_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0098824","article-title":"Prognostic factors for myositis-associated interstitial lung disease","volume":"9","author":"Fujisawa","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.rdc.2025.07.007_bib19","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/acr2.11247","article-title":"A North American cohort of Anti-SAE dermatomyositis: clinical phenotype, testing, and review of cases","volume":"3","author":"Albayda","year":"2021","journal-title":"ACR Open Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2025.07.007_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060442","article-title":"Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome","volume":"8","author":"Hamaguchi","year":"2013","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.rdc.2025.07.007_bib21","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1093\/rheumatology\/ker518","article-title":"The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM","volume":"51","author":"Koga","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.rdc.2025.07.007_bib22","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/acr.22728","article-title":"Anti-Melanoma differentiation-associated gene 5 is associated with rapidly progressive lung disease and poor survival in US patients with amyopathic and myopathic dermatomyositis","volume":"68","author":"Moghadam-Kia","year":"2016","journal-title":"Arthritis Care Res"},{"issue":"11","key":"10.1016\/j.rdc.2025.07.007_bib23","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/s41584-023-01033-0","article-title":"Epidemiology of the idiopathic inflammatory myopathies","volume":"19","author":"Khoo","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.rdc.2025.07.007_bib24","article-title":"Anti-Mi-2 antibodies characterize a distinct clinical subset of dermatomyositis with favourable prognosis","author":"Liang","year":"2020","journal-title":"Eur J Dermatol"},{"issue":"12","key":"10.1016\/j.rdc.2025.07.007_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103464","article-title":"Clinical features of dermatomyositis patients with anti-TIF1 antibodies: a case based comprehensive review","volume":"22","author":"Kilinc","year":"2023","journal-title":"Autoimmun Rev"},{"issue":"9","key":"10.1016\/j.rdc.2025.07.007_bib26","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1007\/s10067-021-05667-x","article-title":"Association of anti-NXP2 antibody with clinical characteristics and outcomes in adult dermatomyositis: results from clinical applications based on a myositis-specific antibody","volume":"40","author":"Yan","year":"2021","journal-title":"Clin Rheumatol"},{"issue":"32","key":"10.1016\/j.rdc.2025.07.007_bib27","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000001144","article-title":"Clinical spectrum time course in Anti Jo-1 positive antisynthetase syndrome: results from an international retrospective multicenter Study","volume":"94","author":"Cavagna","year":"2015","journal-title":"Medicine (Baltim)"},{"issue":"10","key":"10.1016\/j.rdc.2025.07.007_bib28","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.autrev.2012.01.006","article-title":"Comparison of long-term outcome between anti-Jo1- and anti-PL7\/PL12 positive patients with antisynthetase syndrome","volume":"11","author":"Marie","year":"2012","journal-title":"Autoimmun Rev"},{"issue":"5","key":"10.1016\/j.rdc.2025.07.007_bib29","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3899\/jrheum.180778","article-title":"Efficacy of glucocorticoids and calcineurin inhibitors for Anti-aminoacyl-tRNA synthetase antibody-positive Polymyositis\/dermatomyositis-associated interstitial lung disease: a propensity score-matched analysis","volume":"46","author":"Hozumi","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1016\/j.rdc.2025.07.007_bib30","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3389\/fmed.2019.00326","article-title":"Inflammatory myopathy-related interstitial lung disease: from pathophysiology to treatment","volume":"6","author":"Hervier","year":"2019","journal-title":"Front Med"},{"issue":"9","key":"10.1016\/j.rdc.2025.07.007_bib31","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.autrev.2014.03.004","article-title":"The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome","volume":"13","author":"Lega","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.007_bib32","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/MD.0b013e31824d9cec","article-title":"Inflammatory myopathies with anti-Ku antibodies: a prognosis dependent on associated lung disease","volume":"91","author":"Rigolet","year":"2012","journal-title":"Medicine (Baltim)"},{"issue":"5","key":"10.1016\/j.rdc.2025.07.007_bib33","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/rheumatology\/keh575","article-title":"Evaluation of interstitial lung disease in mixed connective tissue disease (MCTD)","volume":"44","author":"Bodolay","year":"2005","journal-title":"Rheumatology (Oxford)"},{"issue":"13","key":"10.1016\/j.rdc.2025.07.007_bib34","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1177\/0961203312456751","article-title":"Distinct phenotypes in mixed connective tissue disease: subgroups and survival","volume":"21","author":"Szodoray","year":"2012","journal-title":"Lupus"},{"issue":"9","key":"10.1016\/j.rdc.2025.07.007_bib35","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1093\/rheumatology\/41.9.1040","article-title":"Inflammatory myositis associated with anti-U1-small nuclear ribonucleoprotein antibodies: a subset of myositis associated with a favourable outcome","volume":"41","author":"Coppo","year":"2002","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.007_bib36","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s10067-018-4267-z","article-title":"Myositis autoantibody profiles and their clinical associations in Greek patients with inflammatory myopathies","volume":"38","author":"Zampeli","year":"2019","journal-title":"Clin Rheumatol"},{"issue":"7","key":"10.1016\/j.rdc.2025.07.007_bib37","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/RHU.0000000000002015","article-title":"Clinical characteristics and prognostic value of Ro52\/SSA antibodies in idiopathic inflammatory myopathies","volume":"29","author":"Pepper","year":"2023","journal-title":"J Clin Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2025.07.007_bib38","doi-asserted-by":"crossref","first-page":"27","DOI":"10.55563\/clinexprheumatol\/bjb2gf","article-title":"Anti-Ro52 antibodies positivity in antisynthetase syndrome: a single centre cohort study","volume":"40 Suppl 134","author":"Bozzalla-Cassione","year":"2022","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.rdc.2025.07.007_bib39","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/08916930600623791","article-title":"In patients with antisynthetase syndrome the occurrence of anti-Ro\/SSA antibodies causes a more severe interstitial lung disease","volume":"39","author":"La Corte","year":"2006","journal-title":"Autoimmunity"},{"key":"10.1016\/j.rdc.2025.07.007_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1399451","article-title":"Clinical features associated with the presence of anti-Ro52 and anti-Ro60 antibodies in Jo-1 antibody-positive anti-synthetase syndrome","volume":"15","author":"Yamaguchi","year":"2024","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.rdc.2025.07.007_bib41","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.semarthrit.2011.09.008","article-title":"Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody","volume":"41","author":"Marie","year":"2012","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.rdc.2025.07.007_bib42","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3899\/jrheum.150844","article-title":"Rituximab in the treatment of Jo1 antibody-associated antisynthetase syndrome: Anti-Ro52 positivity as a marker for severity and treatment response","volume":"43","author":"Bauhammer","year":"2016","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2025.07.007_bib43","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.rdc.2025.07.007_bib44","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.rdc.2025.07.007_bib45","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1183\/09031936.00156312","article-title":"Pulmonary hypertension in antisynthetase syndrome: prevalence, aetiology and survival","volume":"42","author":"Hervier","year":"2013","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.rdc.2025.07.007_bib46","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1378\/chest.08-2740","article-title":"Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis","volume":"136","author":"Mukae","year":"2009","journal-title":"Chest"},{"issue":"136","key":"10.1016\/j.rdc.2025.07.007_bib47","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1183\/16000617.00002015","article-title":"Idiopathic inflammatory myopathies and the lung","volume":"24","author":"Lega","year":"2015","journal-title":"Eur Respir Rev"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.007_bib48","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/resp.12909","article-title":"Bronchoscopy assessment of acute respiratory failure in interstitial lung disease","volume":"22","author":"Arcadu","year":"2017","journal-title":"Respirology"},{"issue":"3100020","key":"10.1016\/j.rdc.2025.07.007_bib49","article-title":"ICU management of the patient with fibrotic interstitial lung disease","volume":"1","author":"Krishnan","year":"2023","journal-title":"Chest Critical Care"},{"issue":"4","key":"10.1016\/j.rdc.2025.07.007_bib50","article-title":"Management of Myositis-Associated interstitial lung disease","volume":"57","author":"Fujisawa","year":"2021","journal-title":"Medicina (Kaunas)"},{"issue":"7","key":"10.1016\/j.rdc.2025.07.007_bib51","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s00296-023-05336-z","article-title":"Management of myositis associated interstitial lung disease","volume":"43","author":"Thong","year":"2023","journal-title":"Rheumatol Int"},{"issue":"6","key":"10.1016\/j.rdc.2025.07.007_bib52","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.rmed.2013.02.015","article-title":"A retrospective review of clinical features and treatment outcomes in steroid-resistant interstitial lung disease from polymyositis\/dermatomyositis","volume":"107","author":"Mira-Avendano","year":"2013","journal-title":"Respir Med"},{"issue":"5","key":"10.1016\/j.rdc.2025.07.007_bib53","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.chest.2019.05.023","article-title":"Long-Term treatment with azathioprine and mycophenolate Mofetil for Myositis-Related interstitial lung disease","volume":"156","author":"Huapaya","year":"2019","journal-title":"Chest"},{"issue":"11","key":"10.1016\/j.rdc.2025.07.007_bib54","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.3899\/jrheum.161217","article-title":"Myositis-associated interstitial lung disease: predictors of failure of conventional treatment and response to tacrolimus in a US cohort","volume":"44","author":"Sharma","year":"2017","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2025.07.007_bib55","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/jamadermatol.2024.0785","article-title":"Methotrexate use and risk of interstitial lung disease in dermatomyositis","volume":"160","author":"Shah","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"4","key":"10.1016\/j.rdc.2025.07.007_bib56","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3899\/jrheum.121026","article-title":"Cyclosporine in anti-Jo1-positive patients with corticosteroid-refractory interstitial lung disease","volume":"40","author":"Cavagna","year":"2013","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.rdc.2025.07.007_bib57","first-page":"436","article-title":"Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease","volume":"31","author":"Labirua-Iturburu","year":"2013","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2025.07.007_bib58","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/resp.13978","article-title":"Prednisolone and tacrolimus versus prednisolone and cyclosporin A to treat polymyositis\/dermatomyositis-associated ILD: a randomized, open-label trial","volume":"26","author":"Fujisawa","year":"2021","journal-title":"Respirology"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.007_bib59","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00296-015-3328-8","article-title":"Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated interstitial lung disease","volume":"36","author":"Go","year":"2016","journal-title":"Rheumatol Int"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.007_bib60","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/rheumatology\/keu166","article-title":"The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis","volume":"54","author":"Kurita","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.rdc.2025.07.007_bib61","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1093\/rheumatology\/kez394","article-title":"Impact of adding tacrolimus to initial treatment of interstitial pneumonitis in polymyositis\/dermatomyositis: a single-arm clinical trial","volume":"59","author":"Takada","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.rdc.2025.07.007_bib62","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1183\/09031936.00163911","article-title":"Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy","volume":"40","author":"Keir","year":"2012","journal-title":"Eur Respir J"},{"issue":"8","key":"10.1016\/j.rdc.2025.07.007_bib63","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/rheumatology\/kev004","article-title":"Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease","volume":"54","author":"Andersson","year":"2015","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.007_bib64","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13075-024-03353-2","article-title":"Rituximab in the treatment of progressive interstitial lung disease associated with the antisynthetase syndrome","volume":"26","author":"Narv\u00e1ez","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.rdc.2025.07.007_bib65","article-title":"Rituximab in the treatment of interstitial lung diseases related to anti-melanoma differentiation-associated gene 5 dermatomyositis: a systematic review","volume":"12","author":"He","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.007_bib66","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"6","key":"10.1016\/j.rdc.2025.07.007_bib67","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02071-2022","article-title":"Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial","volume":"61","author":"Mankikian","year":"2023","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.rdc.2025.07.007_bib68","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11040927","article-title":"Efficacy and safety of Rituximab in Autoimmune disease-associated interstitial lung disease: a prospective cohort Study","volume":"11","author":"Mena-V\u00e1zquez","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.rdc.2025.07.007_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2023.152164","article-title":"Intravenous cyclophosphamide improves functional outcomes in interstitial lung disease related to idiopathic inflammatory myopathies","volume":"59","author":"Moreno-Torres","year":"2023","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.007_bib70","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10067-014-2803-z","article-title":"Cyclophosphamide treatment for idiopathic inflammatory myopathies and related interstitial lung disease: a systematic review","volume":"34","author":"Ge","year":"2015","journal-title":"Clin Rheumatol"},{"issue":"14","key":"10.1016\/j.rdc.2025.07.007_bib71","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa2117912","article-title":"Trial of intravenous immune globulin in dermatomyositis","volume":"387","author":"Aggarwal","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.rdc.2025.07.007_bib72","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1093\/rheumatology\/keab928","article-title":"Intravenous immunoglobulin for interstitial lung diseases of anti-melanoma differentiation-associated gene 5-positive dermatomyositis","volume":"61","author":"Wang","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.rdc.2025.07.007_bib73","first-page":"1682","article-title":"Intravenous immunoglobulin as potential adjunct therapy for interstitial lung disease","volume":"13","author":"Hallowell","year":"2016","journal-title":"Ann Am Thorac Soc"},{"issue":"8","key":"10.1016\/j.rdc.2025.07.007_bib74","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s11926-023-01105-w","article-title":"Intravenous immunoglobulin in idiopathic inflammatory myopathies: a practical guide for clinical use","volume":"25","author":"Gandiga","year":"2023","journal-title":"Curr Rheumatol Rep"},{"issue":"12","key":"10.1016\/j.rdc.2025.07.007_bib75","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/rheumatology\/key188","article-title":"Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis","volume":"57","author":"Kurasawa","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.rdc.2025.07.007_bib76","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.3899\/jrheum.220367","article-title":"A retrospective analysis of outcome in Melanoma differentiation-associated gene 5-Related interstitial lung disease treated with tofacitinib or tacrolimus","volume":"49","author":"Fan","year":"2022","journal-title":"J Rheumatol"},{"issue":"18","key":"10.1016\/j.rdc.2025.07.007_bib77","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rdc.2025.07.007_bib78","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.626953","article-title":"Efficacy and tolerability of nintedanib in idiopathic-inflammatory-myopathy-related interstitial lung disease: a pilot Study","volume":"8","author":"Liang","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.rdc.2025.07.007_bib79","article-title":"Pirfenidone in patients with rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis","volume":"6","author":"Li","year":"2016","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.007_bib80","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1186\/s12890-024-03314-0","article-title":"Design of a randomised controlled hybrid trial of nintedanib in patients with progressive myositis-associated interstitial lung disease","volume":"24","author":"Aggarwal","year":"2024","journal-title":"BMC Pulm Med"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.007_bib81","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.rmed.2013.11.016","article-title":"Pulmonary rehabilitation improves long-term outcomes in interstitial lung disease: a prospective cohort study","volume":"108","author":"Ryerson","year":"2014","journal-title":"Respir Med"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.007_bib82","article-title":"Pulmonary rehabilitation for interstitial lung disease","volume":"2","author":"Dowman","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.007_bib83","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/01.bor.0000152665.41493.49","article-title":"The role of exercise in the rehabilitation of idiopathic inflammatory myopathies","volume":"17","author":"Alexanderson","year":"2005","journal-title":"Curr Opin Rheumatol"},{"issue":"11","key":"10.1016\/j.rdc.2025.07.007_bib84","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.healun.2021.07.005","article-title":"Consensus document for the selection of lung transplant candidates: an update from the International Society for Heart and Lung Transplantation","volume":"40","author":"Leard","year":"2021","journal-title":"J Heart Lung Transplant"},{"issue":"12","key":"10.1016\/j.rdc.2025.07.007_bib85","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1111\/ajt.17177","article-title":"Lung transplantation for interstitial lung disease in idiopathic inflammatory myositis: a cohort study","volume":"22","author":"Rivi\u00e8re","year":"2022","journal-title":"Am J Transplant"},{"issue":"11","key":"10.1016\/j.rdc.2025.07.007_bib86","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.healun.2021.07.014","article-title":"ISHLT consensus document on lung transplantation in patients with connective tissue disease: part I: epidemiology, assessment of extrapulmonary conditions, candidate evaluation, selection criteria, and pathology statements","volume":"40","author":"Crespo","year":"2021","journal-title":"J Heart Lung Transplant"},{"issue":"8","key":"10.1016\/j.rdc.2025.07.007_bib87","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/acr.25348","article-title":"2023 American college of rheumatology (ACR)\/American college of Chest Physicians (CHEST) Guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Care Res"},{"issue":"12","key":"10.1016\/j.rdc.2025.07.007_bib88","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1093\/rheumatology\/keq279","article-title":"Infections in polymyositis and dermatomyositis: analysis of 192 cases","volume":"49","author":"Chen","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.rdc.2025.07.007_bib89","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00403-019-01913-0","article-title":"Association of dermatomyositis with systemic and opportunistic infections in the United States","volume":"311","author":"Ren","year":"2019","journal-title":"Arch Dermatol Res"},{"issue":"11","key":"10.1016\/j.rdc.2025.07.007_bib90","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.4049\/jimmunol.2000802","article-title":"MDA5 is an essential sensor of a pathogen-associated molecular pattern associated with vitality that is necessary for host resistance against Aspergillus fumigatus","volume":"205","author":"Wang","year":"2020","journal-title":"J Immunol"},{"issue":"12","key":"10.1016\/j.rdc.2025.07.007_bib91","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10123176","article-title":"Infection risk in patients with dermatomyositis associated with Anti-MDA5 antibodies: a historical cohort Study","volume":"10","author":"Billet","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.rdc.2025.07.007_bib92","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.2147\/JIR.S460702","article-title":"Prevalence, risk factors, and mortality of invasive pulmonary aspergillosis in patients with Anti-MDA5+ dermatomyositis: a retrospective Study in China","volume":"17","author":"Chen","year":"2024","journal-title":"J Inflamm Res"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.007_bib93","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s13075-021-02606-8","article-title":"High incidence and mortality of Pneumocystis jirovecii infection in anti-MDA5-antibody-positive dermatomyositis: experience from a single center","volume":"23","author":"Huang","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.007_bib94","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s10067-022-06403-9","article-title":"Clinical characteristics of and risk factors for Pneumocystis jirovecii pneumonia in anti-melanoma differentiation-associated gene 5 (Anti-MDA5) antibody-positive dermatomyositis patients: a single-center retrospective study","volume":"42","author":"Li","year":"2023","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.rdc.2025.07.007_bib95","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1504380","article-title":"Pneumocystis jirovecii pneumonia increases the 3-months mortality of anti-MDA5-antibody-positive dermatomyositis patients","volume":"15","author":"Gao","year":"2024","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.rdc.2025.07.007_bib96","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1136\/ard-2022-223335","article-title":"2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases","volume":"82","author":"Fragoulis","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2025.07.007_bib97","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.chest.2021.11.007","article-title":"Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients receiving rituximab","volume":"161","author":"Park","year":"2022","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.007_bib98","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/art.24372","article-title":"Pneumomediastinum in interstitial lung disease associated with dermatomyositis and polymyositis","volume":"61","author":"Le Goff","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.rdc.2025.07.007_bib99","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1136\/thorax-2022-219859","article-title":"Rapidly progressive interstitial lung disease complicated by pulmonary interstitial emphysema in anti-MDA5 amyotrophic dermatomyositis","volume":"78","author":"Kenyon","year":"2023","journal-title":"Thorax"},{"issue":"5","key":"10.1016\/j.rdc.2025.07.007_bib100","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/ard.59.5.372","article-title":"Pneumomediastinum in dermatomyositis: association with cutaneous vasculopathy","volume":"59","author":"Kono","year":"2000","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.007_bib101","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10067-015-3001-3","article-title":"Clinical and serological features of patients with dermatomyositis complicated by spontaneous pneumomediastinum","volume":"35","author":"Ma","year":"2016","journal-title":"Clin Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2025.07.007_bib102","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1093\/rheumatology\/keaa582","article-title":"The long-term prognosis of pneumomediastinum associated with dermatomyositis: a two-centre retrospective cohort study","volume":"60","author":"Li","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.007_bib103","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1136\/hrt.18.2.273","article-title":"Pulmonary hypertension in dermatomyositis","volume":"18","author":"Caldwell","year":"1956","journal-title":"Br Heart J"},{"issue":"4","key":"10.1016\/j.rdc.2025.07.007_bib104","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01324-2024","article-title":"Definition, classification and diagnosis of pulmonary hypertension","volume":"64","author":"Kovacs","year":"2024","journal-title":"Eur Respir J"},{"issue":"39","key":"10.1016\/j.rdc.2025.07.007_bib105","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004911","article-title":"Pulmonary arterial hypertension in idiopathic inflammatory myopathies: data from the French pulmonary hypertension registry and review of the literature","volume":"95","author":"Sanges","year":"2016","journal-title":"Medicine (Baltim)"},{"issue":"11","key":"10.1016\/j.rdc.2025.07.007_bib106","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1111\/1346-8138.16111","article-title":"Successful treatment of pulmonary hypertension with immunosuppressive therapy in a case of anti-synthetase syndrome","volume":"48","author":"Okiyama","year":"2021","journal-title":"J Dermatol"},{"issue":"4","key":"10.1016\/j.rdc.2025.07.007_bib107","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1056\/NEJMoa2008470","article-title":"Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease","volume":"384","author":"Waxman","year":"2021","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.rdc.2025.07.007_bib108","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9072150","article-title":"The impact of Dysphagia in Myositis: a systematic review and meta-analysis","volume":"9","author":"Labeit","year":"2020","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.007_bib109","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"10.1016\/j.rdc.2025.07.007_bib110","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/WNL.48.3.712","article-title":"Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study","volume":"48","author":"Dalakas","year":"1997","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.rdc.2025.07.007_bib111","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1093\/rheumatology\/keaa443","article-title":"Long-term efficacy of adding intravenous immunoglobulins as treatment of refractory dysphagia related to myositis: a retrospective analysis","volume":"60","author":"Giannini","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2025.07.007_bib112","first-page":"393","article-title":"Inflammatory muscle diseases","volume":"4","author":"Dalakas","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.007_bib113","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.nmd.2004.09.006","article-title":"Diaphragmatic dysfunction in patients with idiopathic inflammatory myopathies","volume":"15","author":"Teixeira","year":"2005","journal-title":"Neuromuscul Disord"},{"issue":"9","key":"10.1016\/j.rdc.2025.07.007_bib114","article-title":"Clinico-immunological profile and treatment outcomes of clinically significant diaphragmatic weakness in patients with idiopathic inflammatory myopathies: results from the largest single-center cohort of 16 cases [abstract]","volume":"76","author":"Jain","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2025.07.007_bib115","article-title":"Diaphragmatic ultrasound: a review of its methodological aspects and clinical uses","volume":"46","author":"Santana","year":"2020","journal-title":"J Bras Pneumol"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.007_bib116","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1016\/S2665-9913(23)00322-3","article-title":"Idiopathic inflammatory myopathies: current insights and future frontiers","volume":"6","author":"Connolly","year":"2024","journal-title":"Lancet Rheumatol"},{"issue":"7","key":"10.1016\/j.rdc.2025.07.007_bib117","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1191\/0961203305lu2158oa","article-title":"Polymyositis\/dermatomyositis-associated lung disease: analysis of a series of 81 patients","volume":"14","author":"Selva-O\u2019Callaghan","year":"2005","journal-title":"Lupus"},{"issue":"8","key":"10.1016\/j.rdc.2025.07.007_bib118","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/rheumatology\/39.8.914","article-title":"Respiratory failure due to muscle weakness in inflammatory myopathies: maintenance therapy with home mechanical ventilation","volume":"39","author":"Selva-O\u2019Callaghan","year":"2000","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.007_bib119","doi-asserted-by":"crossref","first-page":"68","DOI":"10.7326\/0003-4819-84-1-68","article-title":"Dermatomyositis and malignancy. A review of the literature","volume":"84","author":"Barnes","year":"1976","journal-title":"Ann Intern Med"},{"issue":"9250","key":"10.1016\/j.rdc.2025.07.007_bib120","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0140-6736(00)03540-6","article-title":"Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study","volume":"357","author":"Hill","year":"2001","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.007_bib121","doi-asserted-by":"crossref","DOI":"10.1186\/ar2987","article-title":"Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan","volume":"12","author":"Chen","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"10.1016\/j.rdc.2025.07.007_bib122","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/rheumatology\/kew215","article-title":"Temporal relationship between cancer and myositis identifies two distinctive subgroups of cancers: impact on cancer risk and survival in patients with myositis","volume":"55","author":"Kang","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.rdc.2025.07.007_bib123","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/RHU.0000000000002075","article-title":"Causality assessment between idiopathic inflammatory myopathies and lung cancer: a bidirectional 2-Sample mendelian randomization","volume":"30","author":"Li","year":"2024","journal-title":"J Clin Rheumatol"},{"issue":"12","key":"10.1016\/j.rdc.2025.07.007_bib124","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/s41584-023-01045-w","article-title":"International Guideline for idiopathic inflammatory myopathy-associated cancer screening: an international myositis assessment and clinical studies Group (IMACS) initiative","volume":"19","author":"Oldroyd","year":"2023","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.007_bib125","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1148\/radiol.2017161659","article-title":"Guidelines for management of incidental pulmonary nodules detected on CT images: from the Fleischner society 2017","volume":"284","author":"MacMahon","year":"2017","journal-title":"Radiology"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X25000547?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X25000547?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T19:23:33Z","timestamp":1761593013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X25000547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":125,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0889857X25000547"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2025.07.007","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Lung Manifestations in Idiopathic Inflammatory Myopathies","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2025.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}